Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

被引：9

作者：

Nagel, Sylke ^{[3
]}

Califano, Raffaele ^{[2
]}

Thatcher, Nicholas ^{[1
]}

Blackhall, Fiona ^{[1
]}

机构：

[1] Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[2] Osped Santa Maria Misericordia, SC Oncol Med, I-06120 Perugia, Italy

[3] Martha Maria Hosp, D-06120 Halle, Germany

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 18期

关键词：

carboplatin; chemotherapy; gemcitabine; non-small-cell lung cancer;

D O I：

10.1517/14656566.8.18.3265

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.

引用

页码：3265 / 3275

页数：11

共 55 条

[1]

[Anonymous], SEMINARS ONCOLOGY S7

[2] Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis [J].

Ardizzoni, Andrea ;

Boni, Luca ;

Tiseo, Marcello ;

Fossella, Frank V. ;

Schiller, Joan H. ;

Paesmans, Marianne ;

Radosavljevic, Davorin ;

Paccagnella, Adriano ;

Zatloukal, Petr ;

Mazzanti, Paola ;

Bisset, Donald ;

Rosell, Rafael .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :847-857

[3] Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer [J].

Bajetta, E ;

Stani, SC ;

De Candis, D ;

Zaffaroni, N ;

Zilembo, N ;

Cortinovis, D ;

Aglione, S ;

Mariani, L ;

Formisano, B ;

Bidoli, P .

ANNALS OF ONCOLOGY, 2003, 14 (02) :242-247

[4] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].

Bepler, Gerold ;

Kusmartseva, Irina ;

Sharma, Swati ;

Gautam, Ashish ;

Cantor, Alan ;

Sharma, Anupama ;

Simon, George .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737

[5]

BERGMAN AM, 1994, ADV EXP MED BIOL, V370, P139

[6] A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemicitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration [J].

Blackhall, Fiona ;

Taylor, Paul ;

Ashcroft, Linda ;

Faivre-Finn, Corinne ;

Burt, Paul ;

Harris, Maggie ;

Summers, Yvonne ;

Appel, Wiebbke ;

Thatcher, Nick .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :S338-S338

[7]

Blackhall Fiona H, 2005, Treat Respir Med, V4, P71, DOI 10.2165/00151829-200504020-00001

[8] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

[9]

Carmichael J, 1996, SEMIN ONCOL, V23, P55

[10]

*CHEM NONSM CELL L, 2000, COCHRANE DB SYST REV, DOI UNSP CD002139

← 1 2 3 4 5 6 →